Immix Biopharma, INC. (IMMX) — 10-K Filings
All 10-K filings from Immix Biopharma, INC.. Browse 3 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (3)
-
Immix Biopharma's NXC-201 Shows 75% Complete Response in AL Amyloidosis Trial
— Mar 25, 2026 Risk: high
Immix Biopharma, Inc. (IMMX) is a clinical-stage biopharmaceutical company focused on CAR-T cell therapy for AL Amyloidosis and other serious diseases. Their le - 10-K Filing — Mar 25, 2025
-
Immix Biopharma Files 2023 Annual Report on Form 10-K
— Mar 29, 2024 Risk: medium
Immix Biopharma, Inc. (IMMX) filed a Annual Report (10-K) with the SEC on March 29, 2024. Immix Biopharma, Inc. filed its 2023 annual report on Form 10-K on Mar
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX